A. Bryskier Clinical Microbiology and Infection

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T

Defining an extended-spectrum β-lactamase

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

Herpes zoster in non-hospitalized children

Defining an extended-spectrum β-lactamase

R. Cantón Clinical Microbiology and Infection

Hydatid disease Clinical Microbiology and Infection

P. Nordmann, L. Poirel Clinical Microbiology and Infection

A.E. Muller, U. Theuretzbacher, J.W. Mouton

Link between intracellular pathogens and cardiovascular diseases

Antibacterial drug discovery: is it all downhill from here?

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Trends in antibiotic prescribing in general internal medicine wards: antibiotic use and indication for prescription B. Maraha, M. Bonten, H. Fiolet,

Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente

A. Bryskier Clinical Microbiology and Infection

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

J.P. Donnelly, B.E. De Pauw Clinical Microbiology and Infection

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Sofie Arens, Jan Verhaegen, Ludo Verbist

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

Training for the infectious diseases speciality in Norway

Cephalosporins: a pharmacological update

Retrospective study of CMV retinitis in patients with AIDS

Epidemiology of opportunistic infections in AIDS patients

Laboratory diagnosis and biosafety issues of biological warfare agents

Sepsis and neutropenia induced by clozapine

Uncommon opportunistic fungi: new nosocomial threats

André Bryskier Clinical Microbiology and Infection

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

Laboratory diagnosis of Clostridium difficile disease

W.A. Craig Clinical Microbiology and Infection

Recent developments in staphylococcal scalded skin syndrome

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

Interactions between cytomegalovirus and the p53 tumor suppressor gene in atherosclerotic vascular disease Inge O. Baas, G. Johan A. Offerhaus, Ralph.

A. Bryskier Clinical Microbiology and Infection

Antibacterial drug discovery in the 21st century

Community-acquired pneumonia: epidemiologic and clinical consideration

Abstracts cont. Clinical Microbiology and Infection

Abstracts cont. Clinical Microbiology and Infection

Training in infectious diseases and tropical medicine in Britain

Antimicrobial drug development – the past, the present, and the future

Definition of the Clinical Antibacterial Spectrum of Activity

Clinical infection services—the Leiden experience

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T

European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis Miles Denton, Kevin G Kerr, Fraser Lewis Clinical.

Clinical Microbiology and Infection

Overview of cefixime use in community-acquired infections

A. Norberg, C.E. Nord, B. Evengård Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

B.A. Cunha Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

The future of diagnostic bacteriology

Vincent Calvez, Marc Grandadam Clinical Microbiology and Infection

Presentation transcript:

Perfecting the ring and extending the antibacterial spectrum: ‘the multiple generations’ A. Bryskier Clinical Microbiology and Infection Volume 6, Pages 13-21 (January 2000) DOI: 10.1111/j.1469-0691.2000.tb02035.x Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Discovery of cephalosporin C. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Cephems: classification 2, chemical classification 1, modification of the ring. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Cephems: classification 3, chemical classification 2, modification of substituents. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 4 Successive waves of cephems. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 5 Cephems: microbiological classification. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 6 Cephems: pharmacokinetics classification. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 7 Cephems: classification: five subgroups A–E. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 8 Cephems group III. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 9 Cephem group III. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 10 Group III B cephems with long apparent elimination half-life. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 11 Cephems: group III; Oxa-1-cephems. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 12 Cephems zwitterionic compounds. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 13 Cephems: group IV (2) classification. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 14 Group IV C-3′ ammonium quaternary cephems. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 15 Cephems group IV: chemical alteration. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 16 Cephems: group V (2): classification Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 17 Cephems: group V. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 18 Cephems: group VII: cephems designed for anti-MRSA activity. Clinical Microbiology and Infection 2000 6, 13-21DOI: (10.1111/j.1469-0691.2000.tb02035.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions